Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 5/20 | 0.49 |
| ▸ | TDO2 | P48775 | 5/20 | 0.49 |
| ▸ | APEX1 | P27695 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29063065 | 0.85 | TNF (0.42) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL25812180 | 0.85 | EIF4A3 (0.42) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL29425105 | 0.83 | EIF4A3 (0.65) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL22395050 | 0.83 | EIF4A3 (0.65) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL15515566 | 0.83 | HPGD (0.56) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL8959558 | 0.81 | XDH (0.47) | EIF4A3TNFRIPK1MAPT | |
| SCHEMBL23346530 | 0.81 | HPGD (0.54) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL7677228 | 0.80 | EIF4A3 (0.61) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL3599395 | 0.80 | EIF4A3 (0.57) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 | |
| SCHEMBL30310477 | 0.80 | EIF4A3 (0.61) | EIF4A3HPGDHSD17B10ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-1061341-C | 1-amino-ethylindole-derivatives | HOFFMANN LA ROCHE (CH) | 2001-01-31 | — | — | CN | disclosed |
| US-5494928-A | FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| CN-1105988-A | 1-amino-ethylindole-derivatives | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | disclosed |
| EP-0655440-A2 | 1-Aminoethylindoles | F. HOFFMANN-LA ROCHE AG (CH) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | EIF4A3 566/4885HPGD 3164/4885HSD17B10 856/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | EIF4A3 608/4885HPGD 1608/4885HSD17B10 1711/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | EIF4A3 608/4885HPGD 1608/4885HSD17B10 1711/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | EIF4A3 608/4885HPGD 1608/4885HSD17B10 1711/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | EIF4A3 608/4885HPGD 1608/4885HSD17B10 1711/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | EIF4A3 582/4885HPGD 1219/4885HSD17B10 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.